Bicara Therapeutics Inc.
NASDAQBCAX fell 14% on Tuesday, closing at $23.76, even as every analyst who updated their model this week lifted their price target — a sharp divergence between what the Street thinks the stock is worth and where the market chose to push it. The sell-off followed an earnings-related event on August 11-12. Yet the analyst response was uniformly constructive. Morgan Stanley raised its…
Snapshot as of 16 Sept 2026
BCAX fell 14% on Tuesday, closing at $23.76, even as every analyst who updated their model this week lifted their price target — a sharp divergence between what the Street thinks the stock is worth and where the market…
BCAX enters its August 12 earnings event in an unusual position: short sellers have been cutting exposure even as the company's own executives took profits at the top. Short interest has dropped sharply — down 6.4% on…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BCAX — free to start on ORTEX.
Sign up for free →Open BCAX on ORTEX